Do not write off the HA platform

There is a body of expert knowledge, (far more expert than me) in which the thinking is along the lines of:

1. Irinetocan is an effective oncology drug with continuing and substantial use.
2. HA Irinetocan proved to be superior to Irinetocan in Alchemia's Phase ll trials.
3. If a Phase lll trial of Irinetocan vs HA Irinetocan was conducted then there is a very high likelihood that the HA drug would prove superior.
4. Such a trial could be considered "low" risk compared to the Phase lll trial which was conducted.

We know the the ill fated Phase lll trial did not do this.

The message is do not write off the HA platform.